ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRY ARS PHARMACEUTICALS INC

Closed 06-28 16:00:00 EDT

8.51

+0.46

+5.71%

盘后8.65

+0.14+1.65%

18:07 EDT

High8.66	Low8.02	Vol4.76M
Open8.33	D1 Closing8.05	Amplitude7.95%
Mkt Cap824.58M	Tradable Cap365.32M	Total Shares96.90M
T/O40.44M	T/O Rate11.08%	Tradable Shares42.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SPRY","market":"US","secType":"STK","nameCN":"ARS PHARMACEUTICALS INC","latestPrice":8.51,"timestamp":1719604800000,"preClose":8.05,"halted":0,"volume":4758174,"hourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.51,"latestTime":"18:07 EDT","volume":1116951,"amount":9505417.663512,"timestamp":1719612420266},"delay":0,"floatShares":42928658,"shares":96895256,"eps":-0.518855,"marketStatus":"Closed","change":0.46,"latestTime":"06-28 16:00:00 EDT","open":8.33,"high":8.66,"low":8.02,"amount":40439906.394786,"amplitude":0.079503,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.518855,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1719820800000},"marketStatusCode":5,"adr":0,"listingDate":1607058000000,"exchange":"NASDAQ","adjPreClose":8.05,"preHourTrading":{"tag":"盘前","latestPrice":8.35,"preClose":8.05,"latestTime":"09:27 EDT","volume":4585,"amount":38949.744645,"timestamp":1719581259400},"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.51,"latestTime":"18:07 EDT","volume":1116951,"amount":9505417.663512,"timestamp":1719612420266},"volumeRatio":8.161441,"optionData":{"bulkOrders":[{"symbol":"SPRY","call":true,"expireDate":1723780800000,"strike":"10.0","timestamp":1719596359825,"price":0.2,"volume":1500,"amount":30000,"type":"+"},{"symbol":"SPRY","call":true,"expireDate":1723780800000,"strike":"10.0","timestamp":1719596359825,"price":0.25,"volume":1500,"amount":37500,"type":"-"}]},"impliedVol":0.3994,"impliedVolPercentile":0.0397},"requestUrl":"/m/hq/s/SPRY/tweets","defaultTab":"tweets","newsList":[{"id":"2447863787","title":"ARS Pharmaceuticals Updates Corporate Presentation Online","url":"https://stock-news.laohu8.com/highlight/detail?id=2447863787","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2447863787?lang=en_us&edition=fundamental","pubTime":"2024-06-29 03:47","pubTimestamp":1719604070,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) just unveiled an update. ARS Pharmaceuticals, Inc. has updated its corporate presentation, which is now accessible on th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ars-pharmaceuticals-updates-corporate-presentation-online?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ars-pharmaceuticals-updates-corporate-presentation-online?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2446507719","title":"ARS Pharmaceuticals' Adrenaline Nasal Spray Receives EMA Committee's Positive Opinion","url":"https://stock-news.laohu8.com/highlight/detail?id=2446507719","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446507719?lang=en_us&edition=fundamental","pubTime":"2024-06-28 21:13","pubTimestamp":1719580433,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a \"positive opinion\" on the company's application for marketing authorization for its adrenaline nasal spray, EURneffy, to treat allergic reactions.The committee's recommendation will be submitted to the European Commission for the formal marketing authorization process, expected in Q3, ARS said.If approved, EURneffy will be made available in Europe in Q4, according to ARS.In the US, the company said the Food and Drug Administration is expected to decide by Oct. 2 on its new drug application for neffy, the company said.The company's shares were 5.6% higher in recent premarket activity.Price: 8.50, Change: +0.45, Percent Change: +5.59","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SPRY","BK4139"],"gpt_icon":0},{"id":"2446550259","title":"BUZZ-ARS Pharma climbs as EU regulator recommends approval for nasal spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2446550259","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446550259?lang=en_us&edition=fundamental","pubTime":"2024-06-28 20:49","pubTimestamp":1719578971,"startTime":"0","endTime":"0","summary":"** Shares of drug developer ARS Pharmaceuticals    rise ~4.8% to $8.44 premarket   ** Co says European Medicines Agency  has recommended approval of its needle-free emergency treatment, EURneffy, for allergic reactions   ** ARS says European Commission, which usually follows EMA's recommendation, is expected to decide on EURneffy in Q3 2024   ** The nasal spray is also under review by U.S. Food and Drug Administration; expected make its decision on Oct. 2   ** Up to last close, stock up 46.9% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BUZZ","SPRY","BK4156"],"gpt_icon":0},{"id":"2446968313","title":"ARS Pharmaceuticals nasal spray for anaphylaxis endorsed in EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2446968313","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446968313?lang=en_us&edition=fundamental","pubTime":"2024-06-28 20:30","pubTimestamp":1719577819,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals  announced Friday an expert panel of the European Medicines Agency  has recommended its EURneffy epinephrine nasal spray for regulatory approval. The Committee for Medicinal Products for Human Use  issued a positive opinion and recommendation for approval of EURneffy for emergency treatment of allergic reactions . The recommendation will now be submitted to the European Commission for the formal marketing authorization process, which is expected to occur in Q3 2024. Richard Lowenthal, CEO of ARS Pharma, said: “Today’s announcement marks a major milestone in the treatment of severe allergies and moves us one step closer to bringing EURneffy to patients in the EU as the first and only needle-free adrenaline option for the emergency treatment of allergic reactions, up to anaphylaxis. EURneffy’s needle-free, smaller form and longer and less temperature-sensitive shelf-life may increase the likelihood that patients will both carry and administer adrenaline, which improve","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1361926717/image_1361926717.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1361926717/image_1361926717.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4120542-chmp-endorses-ars-nasal-spray-for-anaphylaxis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CHMP","SPRY","BK4156","BK4139","BK4087"],"gpt_icon":0},{"id":"2446257095","title":"EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen","url":"https://stock-news.laohu8.com/highlight/detail?id=2446257095","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446257095?lang=en_us&edition=fundamental","pubTime":"2024-06-28 18:57","pubTimestamp":1719572247,"startTime":"0","endTime":"0","summary":"June 28 (Reuters) - ARS Pharmaceuticals    said on Friday the European Medicines Agency (EMA) recommended the approval of its needle-free emergency treatment for allergic reactions. (Reporting by Christy Santhosh; Editing by Nivedita Bhattacharjee)((Christy.Santhosh@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4156","BK4139","SPRY"],"gpt_icon":0},{"id":"2446770875","title":"ARS Pharmaceuticals Gets CHMP Backing for Epinephrine Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2446770875","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446770875?lang=en_us&edition=fundamental","pubTime":"2024-06-28 18:50","pubTimestamp":1719571800,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals has moved a step closer to winning European approval of its proposed epinephrine nasal spray for the emergency treatment of severe allergic reaction.ARS on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the drug, which the San Diego company plans to market as \"EURneffy.\". The European Commission, which generally follows CHMP's advice, will now review the recommendation, with a decision expected in the third quarter.ARS said a green light would make EURneffy the first and only approved needle-free adrenaline option in Europe for the emergency treatment of allergic reactions.ARS said the CHMP's positive opinion is based on the same data package the company submitted to the U.S. Food and Drug Administration in April in its second bid for FDA approval of the drug.The FDA, which last year rejected ARS's initial application, has set a target action date of Oct. 2 for the drug, which ARS plans to marke","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHMP","BK4139","BK4087","SPRY"],"gpt_icon":0},{"id":"2446871332","title":"ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=2446871332","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2446871332?lang=en_us&edition=fundamental","pubTime":"2024-06-26 02:10","pubTimestamp":1719339010,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals stock has recovered since the FDA's Complete Response Letter regarding its epinephrine nasal spray, neffy.Despite competition and a delayed market entry, ARS Pharmaceuticals remain","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1439644606/image_1439644606.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1439644606/image_1439644606.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4700995-ars-pharmaceuticals-on-track-with-neffy-despite-regulatory-hurdles","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BK4007","SPRY","AQST"],"gpt_icon":0},{"id":"2445098072","title":"Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),","url":"https://stock-news.laohu8.com/highlight/detail?id=2445098072","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2445098072?lang=en_us&edition=fundamental","pubTime":"2024-06-24 21:14","pubTimestamp":1719234873,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in ARS Pharmaceuticals implies that they have significant influence over the company's share price. 52% of the business is held by the top 7 shareholders. Every investor in ARS Pharmaceuticals, Inc.  should be aware of the most powerful shareholder groups. With 30% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential .Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.In the chart below, we zoom in on the different ownership groups of ARS Pharmaceuticals.Check out our latest analysis for ARS Pharmaceuticals. What Does The Institutional Ownership Tell Us About ARS Pharmaceuticals?While studying institutional ownership for a company can add value to your research, it is","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/owning-30-shares-institutional-owners-131433242.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","BK4112","SQQQ","LU2095319765.USD","LU2210149790.SGD","BK4139","QID","NQmain","QLD",".IXIC","LU2210150020.SGD","QQQ","SPRY","BK4588","PSQ","MNQmain","TQQQ","BK4585"],"gpt_icon":0},{"id":"2435560351","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435560351","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435560351?lang=en_us&edition=fundamental","pubTime":"2024-05-14 17:31","pubTimestamp":1715679069,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ARS Pharmaceuticals (SPRY – Research Report), Anap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ars-pharmaceuticals-spry-anaptysbio-anab-and-allakos-allk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ars-pharmaceuticals-spry-anaptysbio-anab-and-allakos-allk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLK","HCSG","SPRY","BK4137","BK4139","ANAB"],"gpt_icon":0},{"id":"2435367790","title":"ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2435367790","media":"GuruFocus.com","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435367790?lang=en_us&edition=fundamental","pubTime":"2024-05-13 09:01","pubTimestamp":1715562088,"startTime":"0","endTime":"0","summary":"Net Loss: Reported a net loss of $10.3 million for Q1 2024, slightly above the estimated net loss of $10.44 million.Revenue: Revenue details for Q1 2024 were not provided, unable to compare with the estimated revenue of $1.00 million.EPS: Reported EPS of -$0.11, meeting the estimated EPS of -$0.11 for the quarter.Cash Position: Held $223.6 million in cash and securities as of March 31, 2024, indicating a strong liquidity position to support operations.R&D Expenses: R&D expenses decreased to $5.2 million from $6.6 million in the previous year, reflecting cost efficiency in development activities.G&A Expenses: General and administrative expenses decreased to $8.0 million from $12.2 million year-over-year, due to a pause in pre-commercial launch activities.GuruFocus has detected 3 Warning Signs with SPRY.Research and Development (R&D) expenses for Q1 2024 were reported at $5.2 million, a decrease from $6.6 million in the same period last year, reflecting a strategic reduction in device de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-q1-010128564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":0},{"id":"2434822620","title":"ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434822620","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434822620?lang=en_us&edition=fundamental","pubTime":"2024-05-11 20:24","pubTimestamp":1715430296,"startTime":"0","endTime":"0","summary":"NasdaqGM:SPRY Earnings and Revenue Growth May 11th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US.The company's shares are down 10% from a week ago.Don't forget that there may still be risks. For instance, we've identified   2 warning signs for ARS Pharmaceuticals   you should be aware of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-first-quarter-2024-122456766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SPRY"],"gpt_icon":0},{"id":"2434303128","title":"ARS Pharmaceuticals Inc    expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434303128","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434303128?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:43","pubTimestamp":1715341416,"startTime":"0","endTime":"0","summary":"* ARS Pharmaceuticals Inc     is expected to show a rise in quarterly revenue when it reports  results on August 8 (estimated) for the period ending June 30 2024   * The San Diego California-based  co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2434025710","title":"ARS Pharmaceuticals GAAP EPS of -$0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2434025710","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434025710?lang=en_us&edition=fundamental","pubTime":"2024-05-10 05:31","pubTimestamp":1715290276,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals press release  (NASDAQ:SPRY): Q1  GAAP EPS of -$0.11.\nCash Position: Cash, cash equivalents and short-term investments were $223.6 million as of March 31, 2024.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104269-ars-pharmaceuticals-gaap-eps-of--011","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SPRY","TQQQ","QQQ","QLD","SQQQ","QID","BK4139",".IXIC","NQmain","PSQ","MNQmain"],"gpt_icon":0},{"id":"2434025205","title":"ARS Pharmaceuticals Q1 2024 GAAP EPS $(0.11), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2434025205","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434025205?lang=en_us&edition=fundamental","pubTime":"2024-05-10 05:29","pubTimestamp":1715290165,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38747803/ars-pharmaceuticals-q1-2024-gaap-eps-0-11-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRY"],"gpt_icon":0},{"id":"2434047778","title":"ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2434047778","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434047778?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:05","pubTimestamp":1715285100,"startTime":"0","endTime":"0","summary":"neffy  New Drug Application  and CRL response under review by FDA with anticipated review completion by early October 2024. Response submitted for neffy Marketing Authorization Application  to EMA’s CHMP; CHMP opinion expected in the second quarter of 2024. In April, ARS Pharma submitted its response to the FDA’s Complete Response Letter  issued regarding its NDA for neffy for the treatment of Type I allergic reactions including anaphylaxis. The response addressed all additional requests in FDA’s CRL, which included the positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge conditions, and updated testing that detected no measurable nitrosamine levels, conducted per FDA’s draft guidance issued in August 2023. ARS Pharma anticipates an FDA review period of up to six months, and the PDUFA date is anticipated to be October 2, 2024, based on the submission receipt date of April 2, 2024. Assuming approval on or before the anticipated PDUFA date, ARS Pharma anti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-highlights-neffy-regulatory-200500347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4530","MAA","BK4585","CHMP","BK4087","BK4097","BK4139","BK4121","BK4215","BK4588","CRL","LU2065732104.USD","PRGS","SPRY","LU0390134368.USD"],"gpt_icon":0},{"id":"2431235123","title":"BRIEF-ARS Pharmaceuticals CHMP Opinion On Neffy Marketing Authorization Application Expected In Q2 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2431235123","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431235123?lang=en_us&edition=fundamental","pubTime":"2024-04-30 21:26","pubTimestamp":1714483589,"startTime":"0","endTime":"0","summary":"April 30  - CSL Ltd   :   * ARS PHARMACEUTICALS SUBMITS RESPONSE FOR NEFFY  MARKETING AUTHORIZATION APPLICATION TO EMA’S CHMP AND ENTERS LICENSE AGREEMENT WITH CSL SEQIRUS FOR COMMERCIALIZATION OF NEFFY IN AUSTRALIA AND NEW ZEALAND   * ARS PHARMACEUTICALS INC: CHMP OPINION ON NEFFY MARKETING AUTHORIZATION APPLICATION ANTICIPATED IN Q2 OF 2024Source text for Eikon:    Further company coverage:    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK4139","BK7511","BK7067","BK7501","CSL.AU","SPRY"],"gpt_icon":0},{"id":"2430282900","title":"Insider Trading: ARS Pharmaceuticals’ (NASDAQ:SPRY) Insiders Buy Shares Worth $679K","url":"https://stock-news.laohu8.com/highlight/detail?id=2430282900","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2430282900?lang=en_us&edition=fundamental","pubTime":"2024-04-25 22:30","pubTimestamp":1714055411,"startTime":"0","endTime":"0","summary":"Two of ARS Pharmaceuticals’ (NASDAQ:SPRY) more-than-10% owners, Sarina Tanimoto and Richard Lowenthal, have been actively purchasing SPRY stock. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading-ars-pharmaceuticals-nasdaqspry-insiders-buy-shares-worth-679k?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading-ars-pharmaceuticals-nasdaqspry-insiders-buy-shares-worth-679k?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QLD","BK4588","NQmain","PSQ","TQQQ","QQQ","LU2095319765.USD","LU2210149790.SGD","SPRY","SQQQ","QID","BK4585","NDAQ","MNQmain",".IXIC","LU2210150020.SGD","BK4112"],"gpt_icon":0},{"id":"2429290419","title":"ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Are Analysts Optimistic?","url":"https://stock-news.laohu8.com/highlight/detail?id=2429290419","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2429290419?lang=en_us&edition=fundamental","pubTime":"2024-04-22 19:59","pubTimestamp":1713787189,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse ARS Pharmaceuticals, Inc.'s ( NASDAQ:SPRY ) business as it appears the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-spry/ars-pharmaceuticals/news/ars-pharmaceuticals-inc-nasdaqspry-are-analysts-optimistic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MNQmain","BK4139","BK4585","LU2095319765.USD","LU2210149790.SGD","NDAQ","SPRY","SQQQ","NQmain","BK4588","BK4112",".IXIC","PSQ","QLD","TQQQ","LU2210150020.SGD","QQQ","QID"],"gpt_icon":0},{"id":"2425485835","title":"ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2425485835","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2425485835?lang=en_us&edition=fundamental","pubTime":"2024-04-06 06:30","pubTimestamp":1712356200,"startTime":"0","endTime":"0","summary":"These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from March 28 through April 3, 2024. Source: VerityData. ARS Pharmaceuticals RA Capital Management increased its stake in the biopharmaceutical company to 10,860,977 shares. RA Capital Management did so through the purchase of 1,401,299 ARS Pharmaceuticals shares from March 25 through March 27 at per share prices ranging from $8.89 to $10.Following the purchases, RA Capital Management now owns 11.3% of ARS Pharmaceuticals' outstanding stock. Shares have surged more than 70% so far this year.KalVista Pharmaceuticals TCG Crossover GP I slashed its stake in the pharmaceutical company to 1,345,826 shares. TCG Crossover did so through the sale of 1,355,014 KalVista Pharmaceuticals shares on March 28 at an ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","KALV","ISBC","BK4139","BK4007","NUVL","VERA","SPRY","PHAT","BK4211"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ars-pharma.com","stockEarnings":[{"period":"1week","weight":0.0414},{"period":"1month","weight":-0.1036},{"period":"3month","weight":-0.2123},{"period":"6month","weight":0.469},{"period":"1year","weight":0.2234},{"period":"ytd","weight":0.469}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0313},{"period":"3month","weight":0.0445},{"period":"6month","weight":0.1495},{"period":"1year","weight":0.252},{"period":"ytd","weight":0.1495}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.09589},{"month":2,"riseRate":0.75,"avgChangeRate":0.156334},{"month":3,"riseRate":0.25,"avgChangeRate":-0.081262},{"month":4,"riseRate":0,"avgChangeRate":-0.132409},{"month":5,"riseRate":0.75,"avgChangeRate":0.018154},{"month":6,"riseRate":0.5,"avgChangeRate":0.051531},{"month":7,"riseRate":0.666667,"avgChangeRate":0.098083},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.084853},{"month":9,"riseRate":0,"avgChangeRate":-0.347544},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.004265},{"month":11,"riseRate":0.333333,"avgChangeRate":0.055847},{"month":12,"riseRate":0.666667,"avgChangeRate":0.151109}],"exchange":"NASDAQ","name":"ARS PHARMACEUTICALS INC","nameEN":"ARS PHARMACEUTICALS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ARS PHARMACEUTICALS INC,SPRY,ARS PHARMACEUTICALS INC股票,ARS PHARMACEUTICALS INC股票老虎,ARS PHARMACEUTICALS INC股票老虎国际,ARS PHARMACEUTICALS INC行情,ARS PHARMACEUTICALS INC股票行情,ARS PHARMACEUTICALS INC股价,ARS PHARMACEUTICALS INC股市,ARS PHARMACEUTICALS INC股票价格,ARS PHARMACEUTICALS INC股票交易,ARS PHARMACEUTICALS INC股票购买,ARS PHARMACEUTICALS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ARS PHARMACEUTICALS INC(SPRY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ARS PHARMACEUTICALS INC(SPRY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}